Article
Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study.
Clinical and molecular hepatology - 1 Jan 2021
Baatarkhuu Oidov, Lee Jae Seung, Amarsanaa Jazag, Kim Do Young, Ahn Sang Hoon, Naranzul Nyamsuren, Enkhtuya Damba, Choijamts Nagir, Batbayar Purev, Otgonbayar Radnaa, Saruul Bat-Ulzii, Gantuul Chuluunbaatar, Gegeebadrakh Baljinnyam, Tuvshinbayar Narangerel, Badamsuren Dorjgotov, Ulzmaa Galsan, Otgonbold Jamiyandorj, Han Kwang-Hyub
Abstract excerpt
BACKGROUND/AIMS: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients. METHODS: Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.